“…Midazolam has an extensive first-pass metabolism with oral bioavailability less than 50% (Allonen et al 1981). The macrolide antibiotic erythromycin inhibits the metabolism of midazolam in vitro and also in humans (Byatt et al 1984;Gascon and Dayer 1991;Hiller et al 1990). In a previous study erythromycin treatment increased the area under the midazolam concentration-time curve more than four-fold and peak midazolam concentration almost three-fold after a 15-mg oral dose of midazolam, which caused more proPresented in part at the 18 th International Congress of Chemotherapy, Stockholm, Sweden, June 27-July 2, 1993 Correspondence to: J. T. Backman, Department of Clinical Pharmacology, University of Helsinki, Paasikivenkatu 4, SF-00250 Helsinki, Finland found and prolonged psychomotor effects (Olkkola et al 1993).…”